Lenalidomide hemihydrate

IUPAC name:

3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione;hydrate

CAS No.

847871-99-2

Molecular Weight:

536.5 g.mol−1

Molecular Formula:

C26H28N6O7

Granule:

Mechanism Of Action:

Exhibits immunomodulatory properties.
Activates and increases number of T cells and NK cells
Increases number of NKT cells
Inhibits pro-inflammatory cytokines (e.g., TNF-a, and IL-6) by monocytes
Inhibits cell proliferation and induces apoptosis of tumor cells in vitro and inhibition of tumor growth in vivo, leading to a decrease in tumor burden.
Inhibits angiogenesis by reducing levels of VEGF, TNF-a, and IL-6.

Indication:

Newly diagnosed multiple myeloma(MM) in patients who have undergone/ or not eligible for autologous stem cell transplantation, and Multiple myeloma in patients who have received at least one prior therapy
Myelodysplastic syndromes(MDS)
Mantle cell lymphoma(MCL)
Follicular lymphoma

information

Category: Oncology

January 21, 2024

Desloratadine

Anti-Histamine

Cas No: 100643-71-8

Mechanism Of Action: Desloratadine is a non-sedating, long-acting antihistamine that selectively blocks peripheral histamine H1-receptors. It is the major active metabolite of loratadine and works

Voriconazole

Anti-Microbial

Cas No: 137234-62-9

Mechanism Of Action: Voriconazole is a triazole antifungal agent that works by inhibiting the fungal cytochrome P450 enzyme 14-alpha-lanosterol demethylase1. This enzyme is crucial for

Enoxaparin Sodium

Cardiovascular

Cas No: 679809-58-6

Mechanism Of Action: Enoxaparin, a low molecular weight heparin (LMWH), works primarily by activating antithrombin III, which in turn inhibits factor Xa and IIa (thrombin).

Tirzapatide

Anti-Diabetic

Cas No: 2023788-19-2

Mechanism Of Action : Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This means it mimics the

Lenvatinib Mesylate

Oncology

Cas No: 857890-39-2

Mechanism Of Action: Lenvatinib is classified as a receptor tyrosine kinase (RTK) inhibitor that effectively suppresses the kinase activities of vascular endothelial growth factor (VEGF)

TRAMETINIB DIMETHYL SULFOXIDE

Oncology

Cas No: 1187431-43-1

Mechanism Of Action: Trametinib is identified as a reversible and remarkably selective allosteric inhibitor of MEK1 and MEK2. Through its high-affinity binding to unphosphorylated MEK1